Marks Group Wealth Management Inc Acquires New Stake in BioNTech SE (NASDAQ:BNTX)

Marks Group Wealth Management Inc acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 3,839 shares of the company’s stock, valued at approximately $405,000.

A number of other large investors also recently bought and sold shares of the business. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV raised its position in BioNTech by 4.5% during the 3rd quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV now owns 11,500 shares of the company’s stock valued at $1,249,000 after purchasing an additional 500 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in BioNTech by 3.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock valued at $432,000 after purchasing an additional 148 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in BioNTech by 13.5% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 136,384 shares of the company’s stock valued at $14,817,000 after purchasing an additional 16,179 shares in the last quarter. Raymond James & Associates raised its position in BioNTech by 5.6% during the 3rd quarter. Raymond James & Associates now owns 5,579 shares of the company’s stock valued at $606,000 after purchasing an additional 298 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in BioNTech by 86.5% during the 3rd quarter. Mackenzie Financial Corp now owns 5,131 shares of the company’s stock valued at $558,000 after purchasing an additional 2,380 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 0.2 %

BioNTech stock opened at $88.35 on Wednesday. The stock has a 50-day moving average of $91.05 and a two-hundred day moving average of $96.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The stock has a market cap of $21.00 billion, a PE ratio of 21.48 and a beta of 0.23. BioNTech SE has a one year low of $85.21 and a one year high of $125.83.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. On average, research analysts anticipate that BioNTech SE will post -1.73 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on BNTX shares. BMO Capital Markets reduced their price target on BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research report on Thursday, March 21st. JPMorgan Chase & Co. reduced their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. UBS Group reduced their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $107.00 price target on shares of BioNTech in a research report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, BioNTech currently has an average rating of “Hold” and an average target price of $120.40.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.